Generation of HIV-Resistant Macrophages from IPSCs by Using Transcriptional Gene Silencing and Promoter-Targeted RNA by Higaki, Kei et al.
Title
Generation of HIV-Resistant Macrophages from IPSCs by
Using Transcriptional Gene Silencing and Promoter-Targeted
RNA
Author(s)
Higaki, Kei; Hirao, Masako; Kawana-Tachikawa, Ai; Iriguchi,
Shoichi; Kumagai, Ayako; Ueda, Norihiro; Wang, Bo;
Kamibayashi, Sanae; Watanabe, Akira; Nakauchi, Hiromitsu;
Suzuki, Kazuo; Kaneko, Shin
CitationM lecular Therapy - Nucleic Acids (2018), 12: 793-804
Issue Date2018-09-07
URL http://hdl.handle.net/2433/242854





Generation of HIV-Resistant Macrophages
from IPSCs by Using Transcriptional Gene
Silencing and Promoter-Targeted RNA
Kei Higaki,1,7 Masako Hirao,1,7 Ai Kawana-Tachikawa,2 Shoichi Iriguchi,1 Ayako Kumagai,1 Norihiro Ueda,1
Wang Bo,1 Sanae Kamibayashi,1 Akira Watanabe,3 Hiromitsu Nakauchi,4,5 Kazuo Suzuki,6 and Shin Kaneko1
1Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto
606-8501, Japan; 2AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan; 3Watanabe Laboratory, Department of Life
Science Frontier, Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin, Sakyo-ku, 606-8501 Kyoto, Japan; 4Division of Stem Cell Therapy,
Institute of Medical Science, University of Tokyo, Tokyo, Japan; 5Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine,
Stanford, CA 94305, USA; 6St Vincent’s Centre for Applied Medical Research (AMR), St Vincent’s Hospital, Darlinghurst, NSW 2010, Australia
Highly active antiretroviral therapy (HAART) has markedly
prolonged the prognosis of HIV-1 patients. However, lifelong
dependency on HAART is a continuing challenge, and an effec-
tive therapeutic is much desired. Recently, introduction of
short hairpin RNA (shRNA) targeting the HIV-1 promoter
was found to suppress HIV-1 replication via transcriptional
gene silencing (TGS). The technology is expected to be
applied with hemato-lymphopoietic cell transplantation of
HIV patients to suppress HIV transcription in transplanted
hemato-lymphopoietic cells. Combination of the TGS technol-
ogy with new cell transplantation strategy with induced plurip-
otent stem cell (iPSC)-derived hemato-lymphopoietic cells
might contribute to new gene therapy in the HIV field. In
this study, we evaluated iPSC-derived macrophage functions
and feasibility of TGS technology in macrophages. Human
iPSCs were transduced with shRNAs targeting the HIV-1
promoter region (shPromA) by using a lentiviral vector. The
shPromA-transfected iPSCs were successfully differentiated
into functional macrophages, and they exhibited strong protec-
tion against HIV-1 replication with alteration in the histone
structure of the HIV-1 promoter region to induce heterochro-
matin formation. These results indicated that iPS-derived
macrophage is a useful tool to investigate HIV infection and
protection, and that the TGS technology targeting theHIV pro-
moter is a potential candidate of new gene therapy.
INTRODUCTION
The currently available combined antiviral therapy prevents the
occurrence of symptoms related to AIDS associated with HIV-1
infection.1–3 However, these highly active antiretroviral therapies
(HAARTs) do not impact the viral reservoirs where HIV-1 persists
in its proviral form, and their cessation leads to rapid viral recurrence
except in a few cases.4,5 In addition, previous studies showed the
emergence of a multiple drug-resistant strain of HIV-1 and a range
of adverse effects from the drug-based therapy, which appear to be cu-
mulative.6,7 Therefore, alternative therapeutic approaches for HIV-1
infection are required, and one of the potent candidates is gene
therapy.
Inhibition of HIV-1 through post-transcription gene silencing
(PTGS) has been reported previously.8–12 Small interfering RNAs
(siRNAs) and short hairpin RNA (shRNA) of about 22 nucleotides
targeting HIV-1 structural and accessory genes induce rapid degrada-
tion of mRNA containing complementary sequence and suppress the
production of new virus in vitro. The duration of this effect varies
from 4 to 7 days.8 However, prolongation of this effect has been
achieved using adeno-associated virus or lentiviral vectors to deliver
stably expressed shRNA. HIV-1 can be suppressed for between 14
and 25 days by using this approach. HIV-1 is known to adapt to
environmental pressures, and rapid selection of shRNA escape
mutants has been described in vitro.13,14
We sought an alternative approach of gene therapy to inhibit rapid
viral adaptation to environmental pressures and to suppress viral
replication for extended periods. Transcriptional gene silencing
(TGS) mediated by siRNAs targeting promoter regions of genes of in-
terest was first described in plants.15,16 Previous studies have shown
that siRNAs targeting the promoter region potently suppress HIV-1
via TGS in mammalian cells.17,18 Another study found the suppres-
sive effect of shRNA-mediated TGS on HIV-1 in primary mono-
cyte-derived macrophages (MDMs).19 These studies suggest that
the shRNA-mediated TGS approach to suppress viral replication is
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applicable to a wide range of cell types. We reported previously that
the TGS approach leads to persistence of anti-HIV effect for as
long as 1 year without developing any evidence of escape-resistant
mutation.20 This is because siRNA- and shRNA-mediated TGS
are associated with the induction of epigenetic changes in the HIV
promoter, which are associated with the suppression of HIV-1
transcription.21–23
The viral reservoir in long-lived T cells and myeloid lineage cells plays
an important role in viral recurrence in the absence of HAART.24
A recent study also focused on permanently locking the reservoir in
a silent state by using the TGS approach.19 Resistance to reactivation
of latent HIV-1 infection was observed in HIV-1 J-Lat 9.2 cells trans-
duced with promoter-targeted shRNA.19 Thus, the TGS approach can
provide a means to overcome the current barrier to block HIV-1 tran-
scription in the latently infected reservoir. Recent studies have shown
that TGS targeting the HIV-1 promoter region induced marked
reduction of HIV-1 transcription by altering the histone methylation
and DNA methylation status within the HIV-1 promoter,20–22 which
is characteristic of facultative heterochromatin. However, off-target
activity was also observed in siRNAs designed to induce TGS.25–27
A previous study showed that some siRNA sequences stimulate an
immune cell subset that detects viral nucleic acids and can induce
off-target activity associated with the interferon (IFN) response
through Toll-like receptors (TLRs).25,26 Thus, the possibility of off-
target activity needs to be excluded.
Macrophages play essential roles in the elimination of invading
pathogens and clearance of dying cells.28,29 They are known to be
important for HIV infection. Macrophages and CD4+ T cells have
been reported as the major cellular reservoirs for latent HIV infec-
tion.30–32 Unlike CD4+ T cells, macrophages tend to contribute to
long-term persistence of productive HIV infection because they
are more resistant to the cytopathic effects of the virus and evade
the defensive action of immune responses, with the progeny virus
budding into and accumulating in their endocytic compartments
designated as multivesicular bodies (MVBs).30–32 The macrophage
reservoir is established during the acute stages of HIV infec-
tion.30,31,33 Macrophages also play an important role in the patho-
genesis of HIV-1 infection. Because macrophages can cross the
blood-tissue barrier, they are potent agents of HIV virus delivery
to organs, including the brain.30 They are particularly important
in key immune-privileged sites, including the brain and the male
reproductive tract.34,35 The latter site is significantly enriched with
infected macrophages compared with CD4+ T cells and has the po-
tential to be a major contributor to seminal fluid viral loads and/or
cell-associated viruses that might permit HIV transmission when
CD4+ T cells are limiting.36 Recent research has also revealed that
HIV-infected macrophages can rapidly and efficiently transfer
HIV to CD4+ T cells.37 Although most current studies are focusing
on the CD4+ T cell reservoir, functional cures will require targeting
all of the substantial reservoirs, including macrophages. Therefore,
HIV infection of macrophages plays an important role in viral path-
ogenesis and progression to AIDS.
Embryonic stem cells (ESCs) derived from a blastocyst have the
capacity for self-renewal and for producing derivatives of all three
germ layers.38 They have enabled the study of early human develop-
ment and in vitro analysis of differentiation. However, concerning the
source for cellular therapy, issues of histocompatibility and ethical
problems are associated with the use of human ESCs. Yamanaka
and colleagues39 showed that human somatic cells could be reprog-
rammed into pluripotency by simultaneous introduction of several
factors to yield induced pluripotent stem cells (iPSCs). This
technology enables avoiding issues associated with the use of human
ESCs. Recent studies showed that humanmonocytic lineage cells were
successfully derived from human iPSCs.40,41 They have an advantage
as an experimental model system of HIV infection over MDMs and
monocytic cell lines, which have been typically utilized to study
HIV infection. MDMs differentiated from peripheral bloodmonocyte
cells (PBMCs) isolated from healthy donors42 are highly variable
owing to their inherent heterogeneity. Therefore, they lack in
uniformity in the experimental protocol employed by different
investigators. Conversely, monocytic cell lines such as THP-1 and
U937 provide unlimited cell sources with genetic uniformity and
ease of standardization. However, they do not reflect the HIV-1
infection model of macrophages in vivo as accurately as MDMs.43
Macrophages derived from iPSCs provide an accurate experimental
model system as MDMs and are also capable of unlimited and
uniform expansion. In addition, MDMs have certain drawbacks,
especially when using lentiviral vectors for gene therapy approaches.
Obtaining high rates of lentiviral transduction in macrophages
is difficult because of a range of host restriction factors such as
SAMHD1.44,45
This study aimed to resolve the many current difficulties associated
with the use of MDMs by using iPSC-derived macrophages as a
relatively accessible source of essentially unlimited numbers of
autologous differentiated macrophages. We transduced iPSCs with
a lentiviral vector expressing an shRNA homologous to the nuclear
factor kB (NF-kB)-binding region of HIV-1 promoter. These
shRNA-treated iPSCs were successfully differentiated into macro-
phages. We then assessed the suppression of viral replication in these
cells by using shRNA-mediated TGS with alterations in histone
structure.
RESULTS
Generation of iPSCs Transduced with shRNA Targeting HIV
Promoter
A previous study showed that shPromA, an shRNA homologous
to the NF-kB-binding region of HIV-1 promoter, induced transcrip-
tional suppression of HIV-1 in HIV-infected cells.20,46,47 The vector
backbone of shPromA is a self-inactivated lentiviral vector, which
expresses an EGFP under the control of the Ubc promoter. To
confirm that the transcriptional suppression induced was a conse-
quence of sequence-specific suppression rather than that of off-target
effects, we also designed shPromA-M2, which has two nucleotide
mismatches within the shPromA target sequence (Figure 1A).
To assess the inhibitory effects of shPromA in iPSC-derived
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macrophages, we used an iPSC line established by reprogramming of
T cell as described before48 in this study. We transduced iPSCs with
shPromA and shPromA-M2. The morphologies of the original iPSCs
and those transduced with shPromA and shPromA-M2 are shown in
Figure 1B. EGFP expression was confirmed by fluorescence micro-
scopy (Figure 1B). We also confirmed the sustained expression of
alkaline phosphatase (Figure 1B). All iPSC lines were positive for
SSEA-4, TRA-1-60, and OCT3/4 sufficient markers of pluripotency49
(Figures 1C and 1D). We then evaluated the transduction efficiency
of these vectors in iPSCs. At an MOI of 1, transduction efficiency of
96.3% for shPromA and 96.5% for shPromA-M2 was achieved as
determined by FACS analysis for EGFP expression at 8 days after
transduction (Figure 1E). Only one of the chromosomal abnormal-
ities (47XXX) occurring in pluripotent stem cells was identified
during in vitro culture in whole shPromA and shPromA-M2 trans-
duction experiments (Figure S1A). By simple sub-cloning technique
to select good-shaped colonies, we were able to eliminate abnormal
karyotype iPSCs. We confirmed that frequency of presence of
abnormal karyotype iPSCs by X chromosome fluorescence in situ
hybridization (FISH) assay after sub-cloning was 0.7% in 1,000 cells,
which was similar to levels in PBMCs obtained from healthy donor
(Figure S1B). These observations confirmed the pluripotency of
the iPSCs expressing shPromA and shM2. The shPromA and
shPromA-M2 harboring lentiviral vector in iPSCs and iPSC-
derived macrophages were identified using genomic PCR analysis
(Figure S2).47
Figure 1. Generation of iPSCs Transduced with shRNA Targeting HIV Promoter
(A) Map of the short hairpin RNA (shRNA) in SIN lentivirus vector. SIN vector includes a central polypurine tract (cPPT), U6 promoter (U6 P), shRNA, ubiquitin C promoter (Ubc),
and EGFP. WPREmt stands for mutant woodchuck promoter response element. Lack of the entire enhancer-promoter of the U3 region allows viral genome integration, but
not expression. The sense, hairpin, and anti-sense sequence were inserted downstream of the U6 promoter sequence. Alignment of the shRNA targeting the NF-kB sites
(shPromA) and the two-base mismatch control (shpromM2) is shown below. The red text in the alignment of shPromM2 highlights nucleic acids that differ from the shPromA
sequence. (B) The iPSC lines were observed by alkaline phosphatase (ALP) staining or fluorescence microscopy after transduction with shPromA (PromA), shPromA-M2
(M2), and control (wild-type [WT]). Scale bar, 200 mm. (C) Flow cytometric analysis of human SSEA-4 and TRA-1-60 on unstained untransduced iPSCs, untransduced iPSCs,
and iPSCs transduced with shPromA and with shPromA-M2 (unstained WT, WT, PromA, and M2, respectively). (D) iPSC lines were fixed by ethanol, stained by anti-OCT3/4
antibodies, and analyzed by fluorescence microscopy for OCT3/4 expression after transduction with shPromA (PromA), shPromA-M2 (M2), and control (WT). (E) iPSCs
transduced with shPromA (PromA) and shPromA-M2 (M2) were analyzed for EGFP expression by using flow cytometer (black). Untransduced iPSCs are shown as negative
controls (white).
www.moleculartherapy.org
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Differentiation of Human iPSCs into CD34+ Hematopoietic
Progenitors and Macrophages In Vitro
Following the application of specific in vitro differentiation protocols,
iPSCs are differentiated into macrophages.40,41 This protocol was
applied to assess the capacity of iPSCs expressing shPromA and
shPromA-M2 for macrophage differentiation. For the generation of
hematopoietic stem and/or progenitor cells, iPSCs were co-cultured
on C3H10T1/2 feeder cells in the presence of vascular endothelial
growth factor (VEGF) under 5% oxygen until day 7 and then in the
presence of VEGF, FLT-3L, stem cell factor (SCF), and TPO under
20% oxygen until day 14.48 In this step, we modified the protocol
slightly by supplementing TPO, which has been indicated to play
an important role in the expansion of CD34+ cells,46,50 and optimized
its concentration (data not shown). Dome-like colonies appeared by
days 3–4. Cystic structures were observed after day 10. For the
generation of macrophages, adherent cells were removed, and non-
adherent cells were co-cultured on C3H10T1/2 feeder cells in the
presence of granulocyte-macrophage colony-stimulating factor
(GM-CSF) and macrophage colony stimulating factor (M-CSF)
on day 14 of culture. On day 24, adherent cells were transferred
and cultured in the presence of GM-CSF and M-CSF without
C3H10T1/2 feeder cells. On day 30, morphologically distinct macro-
phages were observed to be attached to the culture plate. This protocol
is shown in Figure 2A.
Characterization of Macrophages Generated from iPSCs
Macrophages derived from iPSCs expressing shPromA and
shPromA-M2 showed adherent, polygonal, and spindle shape under
a microscope (Figures 2B and 2C). Transgene expression efficiency in
iPSC-derived macrophages was determined by EGFP expression.
It was extremely high in iPSC-derived macrophages (95.4% with
shPromA, 97.4% with shPromA-M2) compared with EGFP expres-
sion levels achieved using MDMs (average transduction level 20%,
due to the host restriction factors within MDMs).51 The iPS-derived
macrophages expressed macrophage-associated markers such as
CD11b, CD11c, CD86, and HLA-DR and retained the expression
Figure 2. Differentiation of Human iPSCs into HSCs and Macrophages In Vitro
(A) In vitro macrophage differentiation protocol. (B) May-Giemsa staining of macrophages derived from shPromA (PromA), shPromA-M2 (M2), or original iPSCs (wild-type
[WT]) with an image of monocyte-derived macrophage (MDM). (C) iPSCs transduced with shPromA (PromA), shPromA-M2 (M2), and original iPSCs (WT) were differentiated
into macrophages. EGFP expression was analyzed using fluorescence microscopy. (D) Macrophages derived from iPSCs transduced with shPromA (PromA) and shPromA-
M2 (M2) were analyzed for EGFP expression by using flow cytometer (black). Macrophages derived from wild-type iPSCs are shown as negative controls (white).
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level of CD4 and CCR5 that act as receptors for HIV-1 entry (Figures
3A and 3B; Figure S3). Phagocytic function of iPSC-derived macro-
phages was confirmed using Alexa Flour 594-conjugated Escherichia
coli BioParticles. As observed in the fluorescence microscopic
image shown in Figure 3C, we detected co-localization of captured
BioParticles in iPS-derived macrophages after 1 hr of co-culture.
In addition, we investigated whether the global gene expression pro-
file of iPSC-derived macrophages andMDMs showed any differences.
Transcriptome analysis by mRNA sequencing indicated that iPSC-
derived and TGS-modified macrophages retained similar mRNA
expression profile to that of MDMs (Figure 3D).
Taken together, these findings suggest that macrophages derived
from iPSCs were comparable with primary macrophages in
morphology, cell surface markers, and global gene expression profiles,
which indicated that these cultures could provide susceptible target
cells for HIV infection.
Suppression of Viral Replication in iPS-DerivedMacrophages by
Using shPromA
Next, we assessed whether iPSC-derived macrophages by using
shPromA would be resistant to CCR5-tropic HIV infection. To eval-
uate protection from HIV infection, we challenged iPSC-derived
macrophages with HIV-1 Ba-L virus, which uses CCR5 as well as
CD4 for viral entry. We extracted genomic DNA from infected
iPSC-derived macrophages after day 4 in three experimental groups
and confirmed the presence of HIV-1 DNA across all three experi-
mental groups by using PCR (Figure 4A). We then measured tran-
scriptional activity to compare the HIV-1 transcription level from
the HIV-1 promoter by measuring HIV RNA from the infected
iPSC-derived macrophages at days 4 and 7 after HIV infection (Fig-
ure 4B). The data clearly showed that iPSC-derived macrophages
transfected with shPromA inhibit HIV-1 transcription with around
10 and 20 times reduction compared with that in iPSC-derived mac-
rophages transfected with shPromA-M2 and the mock control,
respectively, at day 11. To confirm this reduction, we also measured
Figure 3. Characterization of Macrophages Generated from iPSCs
(A) Flow cytometric analysis of human CD45, CD86 on macrophages derived from peripheral monocytes, control iPSCs, and iPSCs transduced with shPromA or shPromM2
(MDM,WT, PromA, andM2, respectively). (B) Flow cytometric analysis of human CD11b, CD11c, HLA-DR, and CCR5 onmacrophages derived from iPSCs transduced with
shPromA or shPromM2, and control iPSCs (PromA, M2, and WT, respectively). (C) Macrophages (green) derived from iPSCs transduced with shPromA (upper) and
shPromA-M2 (lower) were incubated with Alexa Flour 594 Escherichia coli (red). The cells were microscopically observed after incubation for 1 hr. BioParticles were co-
localized in macrophages (yellow in merged pictures). Scale bar, 50 mm. (D) Global gene expression of macrophages derived from iPSCs or MDM was analyzed. Heatmaps
show the correlation coefficients between samples.
www.moleculartherapy.org
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the amount of virus released from HIV-1-infected iPSC-derived mac-
rophages in culture supernatants by measuring the reverse transcrip-
tase (RT) activity.52 At day 4 post-transfection, shPromA-transduced
iPSC-derived macrophages showed reduction in virus production
compared with those in control cultures (Figure 4C). This reduction
was sustained at least until day 11. Taken together, these results
indicate the inhibitory effect of shPromA on HIV-1 infection in
iPSC-derived macrophages, which is consistent with our previous
experimental data in MDMs.46,47,53
shPromA Suppressed Viral Replication through TGS
Several studies have shown that TGS mediated by siRNA targeted
to the promoter region is associated with the changes in histone
methylation and deacetylation status around the NF-kB-binding
region.20,53,54 Therefore, we investigated the alteration in histone
methylation status in our model. We performed chromatin immuno-
precipitation (ChIP) assays by using antibodies to histone 3 lysine 27
trimethylation (H3K27me3) on day 8 post-HIV infection. Macro-
phages transduced with shPromA exhibited a significant increase in
H3K27me3 compared with those in the controls (Figure 5A). In addi-
tion, we assessed the histone 3 lysine 9 acetylation (H3K9Ac) and
confirmed that treatment with shPromA was followed by failure of
H3K9Ac enrichment compared with that in controls (Figure 5B).
These data indicated that shPromA-induced TGS of HIV is associated
with histone methylation and histone deacetylation, particularly
induction of H3K27me3 and reduction of H3K9Ac. These data are
also consistent with our previous in vitro experimental data based
on shPromA lentivirus-transduced cell lines.19,47,53,55
No Significant Change Is Observed in the Expression of
NF-kB-Driven Genes by shPromA
Previous studies revealed that long single-strand and double-strand
RNAs are detected by immune cells specialized to recognize viral
nucleic acids through TLR3, TLR7, and TLR8, leading to the trig-
gering of the IFN pathway and induction of non-specific off-target
effects.25,26 shPromA is a long single-strand RNA homologous to
the NF-kB-binding region in HIV long terminal repeat (LTR); it
might potentially alter the expression of other NF-kB-driven genes
and induce sequence-specific off-target effects.27 RNA sequencing
of shPromA-transduced iPSC-derived macrophages was used to
exclude the sequence-specific or non-specific off-target effects
mediated by shPromA. We examined the transcription level of 86
NF-kB-driven genes, including IFN genes (Table S1), but did not
detect any significant difference in the transcription of these
NF-kB-driven genes (Figures 6A–6C). The data were concordant
with a previous report that shPromA does not alter the expression
Figure 4. Suppression of Viral Replication in iPS-Derived Macrophages Expressing shPromA
Macrophages derived from iPSCs transduced with shPromA or shPromM2, and control iPSCs (PromA, M2, and WT, respectively) were challenged with an R5-tropic HIV-1
Ba-L virus. (A) Real-time PCR of the gag region confirms similar levels of integrated HIV-1 provirus presented in all samples. However, HIV-1 replication was inhibited in
PromA, as determined by (B) viral mRNA levels normalized to GAPDH and (C) viral reverse transcriptase activity. Two-way ANOVA revealed statistically significant interaction
between transduction of shRNA and viral mRNA levels or reverse transcriptase activity (p < 0.01).
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of other NF-kB-driven genes by targeting other NF-kB-binding mo-
tifs in host genes.47 These results strongly support that the observed
HIV-1 suppression is not a result of off-target effects induced by
shPromA.
DISCUSSION
Previous studies have shown TGS of HIV-1 in HeLa or T cell lines by
using shRNA targeting the HIV-1 promoter region through the in-
duction of epigenetic modifications.56,57 Suppression of viral replica-
tion through the TGS pathway was also observed in an in vivo NOD/
Scid/Jak3-deficient (NOJ) humanized mouse model.47 In this study,
we showed HIV-1 gene silencing via the TGS pathway in iPSC-
derived macrophages. The target sequence of shRNA mediating
TGS was located within the NF-kB-binding region of the HIV-1 pro-
moter, which induces the activation of the HIV-1 LTR response to
NF-kB inducers.58 Expression of the promoter-targeted shRNA did
not show any adverse effects on the morphology of iPSCs, which
showed round colonies and tight edges, as shown in Figure 1B.
Moreover, iPSCs expressing promoter-targeted shRNA were positive
for markers of pluripotency as measured by immunofluorescence.
Therefore, the expression of promoter-targeted shRNA did not affect
their pluripotency or morphology.
Another major concern with transduction of shRNA-expressing
vectors is the possibility of their effect on differentiation into pheno-
typically and functionally normal macrophages. Following the appli-
cation of specific in vitro differentiation protocols, shRNA-expressing
iPSCs were successfully differentiated into macrophages at a rate
similar to that of control iPSCs. The macrophages derived from
iPSCs were comparable with MDMs with respect to morphology,
cell surface markers, and phagocytic capability. We observed
no gene silencing of EGFP throughout their differentiation into
macrophages.
Figure 5. shPromA Suppressed Viral Replication
through TGS
Chromatin immunoprecipitation assays were performed
on macrophages derived from iPSCs transduced with
shPromA or shPromM2, and control iPSCs (PromA, M2,
and WT, respectively) at day 4. DNA fragments from
whole-cell extracts were co-precipitated against (A) his-
tone 3 lysine 9 acetylation (H3K9Ac) and (B) histone 3
lysine 27 trimethylation (H3K27me3). Each value shown is
the relative enrichment normalized to the value obtained
from mock transfection. *p < 0.05; **p < 0.01.
Upon challenge with HIV-1 infection in iPSC-
derived macrophages expressing shPromA
compared with that in original iPSC-derived
macrophages and iPSC-derived macrophages
with two-base mismatched control (shPromA-
M2), we observed strong suppression of
HIV-1 transcriptional activity measured using
viral mRNA analysis. We also found strong
reduction in viral replication measured using RT assay by using
culture supernatants. We confirmed that this inhibitory effect on
viral replication was due to the induction of TGS with alteration in
histone methylation and acetylation status. Some studies have
shown sequence-specific or sequence-nonspecific off-target effects
of siRNAs designed to induce TGS.25–27 We confirmed that the
expression of promoter-targeted shRNA did not have any significant
off-target effects, as determined by the expression analysis of 86
NF-kB-driven genes, including IFN genes.
Viral entry of HIV-1 requires binding to a CD4 receptor and either
CCR5 or CXCR4. Homozygosis for a 32-bp deletion in the CCR5
allele confers high resistance against HIV-1 acquisition,59 which
makes CCR5 an attractive target for gene therapy of HIV. A previous
study showed allogeneic stem cell transplantation in a patient with
HIV infection and acute myeloid leukemia from a donor who was ho-
mozygous for CCR5 delta32. In this patient, no active, replicating
HIV could be detected for 20 months after transplantation and
discontinuation of antiretroviral therapy.60 This result indicates that
the generation of immune cells resistant to HIV infection can be a
potential therapeutic application for the treatment of chronic HIV
infections.
For generating HIV-resistant immune cells, previous studies have
used CCR5 gene modification in HSPCs, CD4+ T lymphocytes, and
iPSCs and showed their resistance against viral infection.61–63 How-
ever, CCR gene modification in immune cells cannot prevent the
advent of non-CCR5-tropic variants, as observed in a patient
at 20 months after allogeneic stem cell transplantation of CCR5
delta32.60 In addition, CCR3, as well as CCR5, has been reported to
promote efficient infection of the CNS by HIV-1.64 These data
strongly suggest that gene therapy approaches can inhibit HIV-1 en-
try into human cells. However, less impact would be observed on the
www.moleculartherapy.org
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reduction of the established latently infected reservoir population
when these approaches targeting HIV-1 entry inhibition are used.
Therefore, our shRNA-mediated TGS approach is an alternative
potent candidate gene therapy for HIV-1 infection aiming to control
HIV-1 transcription under a silenced mode as observed in latent
HIV-1 infection.
The iPSC-derived macrophage model was utilized to confirm the
inhibitory effect of shPromA delivered by a lentiviral vector. To
further elucidate this approach, we also intend to investigate the
use of T cells derived from iPSCs at the double-positive (DP) stage.
Previously, we established a culture protocol to generate T cells at
the DP stage.48 Following the application of our protocol,
shPromA-treated iPSCs will be differentiated into T cells at the DP
stage. If viral suppression is recapitulated in iPSC-derived T cells at
the DP stage, an increased emphasis on aiming to achieve functional
care by iPSC-based gene therapy will be strongly suggested.
We also observed that transduction efficiency in iPSC-derived macro-
phages after transfection with the lentiviral vector, as determined by
GFP-expressing cells, was extremely high compared with the GFP
expression levels obtained when MDMs were used. We usually
achieve transfection efficiency of around 20% because of host restric-
tion factors such as SAMHD1. We also expect a high level of trans-
duction efficiency in differentiated T cells at the DP stage derived
from shPromA-transfected iPSCs.
In this study, we showed the inhibitory effect of promoter-targeted
shRNA on HIV-1 replication in iPSC-derived macrophages through
the TGS pathway. This concept is not limited to macrophages derived
from iPSCs andmight be extended to T cells at the DP stage or even to
hematopoietic stem cells (HSCs) derived from iPSCs, if optimization
of differential conditions can be achieved. Generation of HSCs
derived from shPromA-treated iPSCs might enable the reconstitution
of the immune systemwith immune cells resistant to HIV-1 infection.
The data presented in this study emphasize the advantages of gener-
ating HIV-1-resistant HSCs derived from iPSCs as therapeutic cells
for HIV gene therapy.
MATERIALS AND METHODS
Human iPSCs
In this study, we used the human iPSC line 4GAD1-4 obtained from a
monoclonal T cell clone specific to glutamic acid decarboxylase
(GAD) by using a Sendai virus vector, as described previously.48
iPSCs were maintained on tissue culture dishes coated with mouse
embryonic fibroblasts (MEFs) or Matrigel (Becton Dickinson) in
Figure 6. RNA Sequence of the 86 NF-kB-Driven Genes, Including the IFN Genes
Scatterplot of log transformation of the relative expression of mRNA from 86 NF-kB-driven genes. No significant difference was noted in the relative expression (A) between
macrophages derived from untransduced iPSCs (wild-type [WT]) and those derived from iPSCs transduced with shPromA (PromA); (B) between macrophages derived from
iPSCs transduced with shPromA (PromA) and those derived from iPSCs transduced with shPromA-M2 (M2); and (C) between macrophages derived from iPSCs transduced
with shPromA-M2 (M2) and those derived from untransduced iPSCs (WT).
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mTeSR1 serum-free medium (STEMCELL Technologies). Some
PBMC samples were obtained from healthy volunteers who provided
written informed consent. Research was approved by the Kyoto
University School of Medicine ethical committee (no. G590).
Construction of shRNA-Expressing Lentiviral Vector
The construction of lentiviral vectors by using the following sense and
antisense DNA oligomers has been described previously47: shPromA
sense, 50-GAT CCG GGA CTT TCC GCT GGG GAC TTC TGT
GAA GCC ACA GAT GGG AAG TCC CCA GCG GAA AGT
CCC TTT TTT AT-30; shPromA antisense, 50-CGA TAA AAA
AGG GAC TTT CCG CTG GGG ACT TCC CAT CTG TGG CTT
CAC AGA AGT CCC CAG CGG AAA GTC CCG-30 and shM2
sense, 50-GAT CCG GGA CTT TAA GCT GGG GAC TTC TGT
GAA GCC ACA GAT GGG AAG TCC CCA GCG GAA AGT
CCC TTT TTT AT-30; shM2 antisense, 50- CGA TAA AAA AGG
GAC TTT AAG CTG GGG ACT TCC CAT CTG TGG CTT CAC
AGA AGT CCC CAG CTT AAA GTC CCG-30.
Lentiviral Transduction into iPSCs
iPSCs at 5  105 cells on Matrigel-coated culture plates were sus-
pended in 100 mL of StemFit (Ajinomoto). After lentiviral suspension
(MOI = 1) was added, these tubes were rotated at 37C for 20 min by
using a Macsmix Tube Rotator (Miltenyi Biotec). After rotation, the
iPSCs were transferred to Matrigel-coated culture plates in StemFit
culture medium supplemented with Y-27632 Rho kinase inhibitor
(ROCKi; Tocris, Bristol, UK). After a few days of culture, GFP-posi-
tive iPSCs were sorted by flow cytometry analysis.
Hematopoietic Differentiation and Generation of Macrophages
from iPSCs
To induce hematopoietic differentiation from human iPSCs, we
slightly modified a previously described method.65 In brief, small
clumps (<100 cells) of iPSCs maintained on MEFs were collected
and co-cultured on C3H10T1/2 cells in embryoid body (EB)
medium (Iscove’s modified Dulbecco’s medium) containing VEGF
(20 ng/mL). On day 7, SCF (50 ng/mL), FLT-3L (50 ng/mL), and/
or TPO (2 or 20 ng/mL) was added to the culture. On day 14, hemato-
poietic progenitor cells in the iPSC sacs were collected and transferred
to a newly prepared C3H10T1/2 layer in the presence of M-CSF
(50 ng/mL) and GM-CSF (50 ng/mL). On day 24, after the floating
and loosely adherent cells were removed, firmly adherent cells were
collected and transferred to low-attachment six-well culture plates
(Corning Costar Ultra-Low attachment multiwell culture plates;
Sigma-Aldrich) in the presence of GM-CSF (50 ng/mL) and M-CSF
(50 ng/mL), and they showed macrophage-like morphology with
fringes within 5 days.
Flow Cytometry
Flow cytometric data were acquired using FACScan (BD Biosciences,
Bedford, MA, USA) and then analyzed using FlowJo software (Tree
Star). The following monoclonal antibodies (mAbs) were purchased
from BD Pharmingen (San Diego, CA, USA), Beckman Coulter
(Miami, FL, USA), eBioscience (San Diego, CA, USA), Miltenyi Bio-
tec (Auburn, CA, USA), R&D Systems (Minneapolis, MN, USA), or
Caltag Laboratories (Hamburg, Germany): SSEA4-PE, TRA-1-60-
Alexa Flour 648, CD45-allophycocyanin (APC)-Cy7, CD14-PB,
CD11b-PE, CD11c-APC, CD68-APC, HLA-DR-BV605, and CCR-
PerCP-Cy5.5.
Analysis of Phagocytosis Function in Myeloid Lineage Cells
Derived from iPSCs
Macrophages derived from iPSCs were incubated for 1 hr with
BioParticles (E. coli strain K-12 BioParticles, Alexa Flour 594 conju-
gated, catalog [Cat] #E-23370; Life Technologies), washed three times
with PBS, and observed using an IX71 invertedmicroscope (Olympus).
HIV-1 Infection and Viral Quantification
iPSC-derived macrophages (1  105) were infected with HIV-1 Ba-L
virus (1 ng p24 virus), and infection was allowed to establish for
2 hr.55 qPCR was performed to analyze the HIV-1 DNA levels. In-
fected cells were collected 24 hr after infection, and genomic DNA
was extracted (QIAamp DNA Blood Mini Kit; QIAGEN). The inte-
grated HIV-1 genome was analyzed using real-time PCR by using a
TaqMan probe with a standard curve generated using serial dilutions
of the HIV-1 molecular clone plasmid (pNL4-3, Cat No.114; NIH
AIDS Reagent Program). The following primers were used: HIV
gag forward primer, 50-AGTGGGGGGACATCAAGCAGCCATG
CAAAT-30; HIV gag reverse primer, 50-TACTAGTAGTTCCTGC
TATGTCACTTCC-30. On days 0, 4, 7, and 11, tissue culture super-
natants were sampled and analyzed for reverse transcriptase activity,
as described previously.52 The levels of HIV-1 mRNA were measured
using qRT-PCR by using the HIV gag primers (shown above). Levels
of GAPDH mRNA were measured as an internal control. To plot
standard curves, we infected PM-1 cells (8  106 cells) with HIV-1
(NL4-3, 100 ng p24).
ChIP Assay
On day 4 after infection, macrophages were collected, and a ChIP
assay was performed using a ChIP assay kit (Merck Millipore), as
described previously.53 In brief, cultures were fixed with 1% formal-
dehyde for 10 min at room temperature and incubated for 5 min
with 0.125 mol/L glycine; after three washes with cold PBS, the pellets
were resuspended in 400 mL of SDS with protease inhibitor cocktail
(Roche). The lysate was then sonicated to shear DNA for 4 min by
using a 90-W ultrasonic processor (Qsonica Sonicator Q700; Qson-
ica, Farmingdale, NY, USA). The lysate was then centrifuged at
10,000 g for 5min. The resulting supernatant was divided into three
aliquots, and anti-acetylation-H3K9 (Millipore), anti-trimethylation
H3K27 (Millipore), and no antibody (control) were added to the
respective aliquots. Samples were incubated with Protein A-Agarose
beads (Upstate, Charlottesville, VA, USA). The beads were then
washed, and DNA was extracted using the QIAprep PCR extraction
kit (QIAGEN). Real-time PCR analysis was performed using a Sensi-
FAST SyBr kit (Bioline, NSW, Australia). The following primers were
used: LTR forward, 50-TACAAGGGACTTTCCGCTGG-30; LTR
reverse, 50-TTGAGGCTTAAGCAGTGGG-30. The PCR conditions
were as follows: 94C for 2 min, followed by 45 cycles of 95C for
www.moleculartherapy.org
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7 s and 58C for 20 s. To generate a standard curve, we used diluted
aliquots of HIV-1 molecular clone plasmid (pNL4-3). The results of
the PCR in aliquots with no antibody were subtracted from the results
of interest.
RNA Sequencing
mRNA from the macrophages was extracted using an RNeasy mini
kit (QIAGEN). cDNA was synthesized using SMARTer Ultra Low
Input RNA and sequenced using an Illumina Sequencing-HV kit
(Clontech, Mountain View, CA, USA), after which the Illumina
library was prepared using a Low Input Library Prep kit (Clontech).
The libraries were sequenced using HiSeq 2500 in 101 cycle Single-
Read mode. All sequence reads were extracted in FASTQ format by
using BCL2FASTQ Conversion Software 1.8.4 in the CASAVA
1.8.2 pipeline. The sequence reads were mapped to hg19 reference
genome, downloaded on December 10, 2012, by using TopHat
v2.0.8b,66 and quantified using RPKMforGenes.67
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